Skip to main content
SpringerLink
Log in

Central Nervous System Lymphoma

  • Chapter
  • First Online:
Lymphoma

Part of the book series: Current Clinical Oncology ((CCO,volume 43))

  • 2412 Accesses

Abstract

Central nervous system (CNS) lymphomas comprise a diverse group of primary or secondary neoplasms of the brain and leptomeninges. Primary CNS lymphoma, most commonly a diffuse large B-cell lymphoma (DLBCL) confined to the CNS, is treated by chemotherapy or chemoradiation strategies that are different from the approaches used for DLBCL elsewhere in the body. Secondary CNS lymphoma occurs when a systemic lymphoma disseminates to the leptomeninges or the brain. The risk of secondary CNS lymphoma is dependent on the lymphoma subtype and the anatomic location. Although radiation and intrathecal or intravenous chemotherapy are commonly utilized in the treatment of secondary CNS lymphoma, prognosis remains poor. Neurotoxicity is a significant complication of CNS-directed therapy for primary and secondary CNS lymphomas and the risk is highest in older patients treated with whole brain radiation therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Central Brain Tumor Registry of the United States (CBTRUS) statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2007, Hinsdale, IL. http://www.cbtrus.org

  2. Kadan-Lottick N, Sklusarek M, Gurney J. Decreasing incidence rates of primary central nervous system lymphoma. Cancer. 2002;95:193–202.

    Article  PubMed  Google Scholar 

  3. Panageas KS, Elkin EB, DeAngelis LM, Ben-Porat L, Abrey LE. Trends in survival from primary central nervous system lymphoma, 1975–1999: a population-based analysis. Cancer. 2005;104:2466–72.

    Article  PubMed  Google Scholar 

  4. Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H. Pathology with clinical correlations of primary central nervous system non-­Hodgkin’s lymphoma. The Massachusetts General Hospital experience 1958–1989. Cancer. 1994;74:1383–97.

    Article  PubMed  CAS  Google Scholar 

  5. Camilleri-Broët S, Crinière E, Broët P, et al. A uniform activated B-cell–like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107:190–6.

    Article  PubMed  Google Scholar 

  6. Rubenstein J, Fridlyand J, Shen A, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006;107:3716–23.

    Article  PubMed  CAS  Google Scholar 

  7. Fischer L, Hummel M, Korfel A, Lenze D, Joehrens K, Thiel E. Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro Oncol. 2011;13(10):1090–8.

    Article  PubMed  CAS  Google Scholar 

  8. Tun HW, Personett D, Baskerville KA, et al. Pathway analysis of primary central nervous system lymphoma. Blood. 2008;111:3200–10.

    Article  PubMed  CAS  Google Scholar 

  9. Newell M, Hoy J, Cooper S, et al. Human immuno­deficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer. 2004;100:2627–34.

    Article  PubMed  Google Scholar 

  10. Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg. 2000;92:261–6.

    Article  PubMed  CAS  Google Scholar 

  11. Abrey L, Batchelor T, Ferreri A, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034–43.

    Article  PubMed  Google Scholar 

  12. Mohile NA, Deangelis LM, Abrey LE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol. 2008;10(2):223–8.

    Article  PubMed  Google Scholar 

  13. Jahnke K, Hummel M, Korfel A, et al. Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J Clin Oncol. 2006;24:4754–7.

    Article  PubMed  CAS  Google Scholar 

  14. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med. 1993;119:1093–104.

    Article  PubMed  CAS  Google Scholar 

  15. Barajas Jr RF, Rubenstein JL, Chang JS, Hwang J, Cha S. Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol. 2009;31(1):60–6.

    Article  PubMed  Google Scholar 

  16. Kuker W, Nagele T, Korfel A, et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol. 2005;72:169–77.

    Article  PubMed  Google Scholar 

  17. Ferreri A, Blay J, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266–72.

    Article  PubMed  Google Scholar 

  18. Abrey L, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24(36):5711–5.

    Article  PubMed  Google Scholar 

  19. Braaten K, Betensky R, de Leval L, et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res. 2003;9:1063–9.

    PubMed  CAS  Google Scholar 

  20. Larocca LM, Capello D, Rinelli A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood. 1998;92:1011–9.

    PubMed  CAS  Google Scholar 

  21. Takeshita M, Iwashita A, Kurihara K, et al. Histologic and immunohistologic findings and prognosis of 40 cases of gastric large B-cell lymphoma. Am J Surg Pathol. 2000;24:1641–69.

    Article  PubMed  CAS  Google Scholar 

  22. Levy O, Deangelis LM, Filippa DA, Panageas KS, Abrey LE. Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer. 2007;112:151–6.

    Article  Google Scholar 

  23. Lin C, Kuo K, Chuang S, et al. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of the central nervous system origin and peripheral nodal origin. Clin Cancer Res. 2006;12:1152–6.

    Article  PubMed  CAS  Google Scholar 

  24. Rosenwald A, Wright G, Chan W. Lymphoma/leukemia molecular profiling project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–47.

    Article  PubMed  Google Scholar 

  25. Lossos I, Jones C, Warnke R, et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood. 2001;98:945–51.

    Article  PubMed  CAS  Google Scholar 

  26. Cady FM, O’Neill BP, Law ME, et al. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol. 2008;26:4814–9.

    Article  PubMed  CAS  Google Scholar 

  27. Courts C, Brunn A, Montesinos-Rongen M, et al. Preferential expression of truncated isoforms of FOXP1 in primary central nervous system lymphoma. J Neuropathol Exp Neurol. 2009;68:972–6.

    Article  PubMed  CAS  Google Scholar 

  28. Batchelor T, Loeffler J. Primary CNS lymphoma. J Clin Oncol. 2006;24:1281–8.

    Article  PubMed  CAS  Google Scholar 

  29. Ferreri A, Abrey L, Blay J, et al. Summary statement on primary central nervous system lymphomas from the eighth international conference on malignant lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol. 2003;21:2407–14.

    Article  PubMed  Google Scholar 

  30. Beela MS, Carson K, Grossman SA. Initial response to glucocorticoids: a potentially important prognostic factor in patients with primary CNS lymphoma. Cancer. 2006;106:383–7.

    Article  Google Scholar 

  31. Nelson D, Martz K, Bonner H, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23:9–17.

    Article  PubMed  CAS  Google Scholar 

  32. Shibamoto Y, Ogino H, Hasegawa M, et al. Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys. 2005;62:809–13.

    Article  PubMed  Google Scholar 

  33. Ishikawa H, Hasegawa M, Tamaki Y, et al. Comparable outcomes of radiation therapy without high-dose methotrexate for patients with primary central nervous system lymphoma. Jpn J Clin Oncol. 2003;33:443–9.

    Article  PubMed  Google Scholar 

  34. Bessell E, Lopez-Guillermo A, Villa S, et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol. 2002;20:231–6.

    Article  PubMed  CAS  Google Scholar 

  35. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512–20.

    Article  PubMed  CAS  Google Scholar 

  36. Gerstner ER, Carson K, Grossman S, Batchelor TT. Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology. 2008;70:401–2.

    Article  PubMed  Google Scholar 

  37. Batchelor T, Carson K, O’Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiation therapy: a report of the NABTT 96–07. J Clin Oncol. 2003;21:1044–9.

    Article  PubMed  CAS  Google Scholar 

  38. Pels H, Schmidt-Wolf IG, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21:4489–95.

    Article  PubMed  CAS  Google Scholar 

  39. DeAngelis L, Seiferheld W, Schold S, Fisher B, Schultz C. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93–10. J Clin Oncol. 2002;20:4643–8.

    Article  PubMed  Google Scholar 

  40. Shah G, Yahalom J, Correa D, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25:4730–5.

    Article  PubMed  CAS  Google Scholar 

  41. Mead GM, Bleehen NM, Gregor A, et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer. 2000;89:1359–70.

    Article  PubMed  CAS  Google Scholar 

  42. Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11:1036–47.

    Article  PubMed  CAS  Google Scholar 

  43. Monje M, Mizumatsu S, Fike J, Palmer T. Irradiation induces neural precursor cell dysfunction. Nat Med. 2002;8:955–62.

    Article  PubMed  CAS  Google Scholar 

  44. Hoang-Xuan K, Taillandier L, Chinot O, et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol. 2003;21:2726–31.

    Article  PubMed  CAS  Google Scholar 

  45. Issa S SA, Karch J, Kachoch C, Shuman M, Damon L, Rubenstein JL.Treatment of primary CNS lymphoma with induction high-dose methotrexate, temozolomide, rituximab followed by consolidation cytarabine/etoposide. J Clin Oncol. 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Vol 24, No 18S (June 20 Supplement); 2007.

    Google Scholar 

  46. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007;25:1350–6.

    Article  PubMed  CAS  Google Scholar 

  47. Reni M, Mason W, Zaja F, et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer. 2004;40:1682–8.

    Article  PubMed  CAS  Google Scholar 

  48. Abrey L, Moskowitz C, Mason W, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003;21:4151–6.

    Article  PubMed  CAS  Google Scholar 

  49. Montemurro M, Kiefer T, Schüler F, et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol. 2007;18:665–71.

    Article  PubMed  CAS  Google Scholar 

  50. Illerhaus G, Marks R, Ihorst G, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006;24:3865–70.

    Article  PubMed  CAS  Google Scholar 

  51. Illerhaus G, Müller F, Feuerhake F, Schäfer AO, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008;93:147–8.

    Article  PubMed  CAS  Google Scholar 

  52. Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006;38:417–20.

    Article  PubMed  CAS  Google Scholar 

  53. Stewart D, Forsyth P, Chaudhry A, et al. High dose thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic stem cell transplantation (ASCT) without whole brain radiotherapy (WBRT) for primary central nervous system lymphoma (PCNSL). ASH Annual Meeting Abst. 2004;104:911.

    Google Scholar 

  54. Cheng T, Forsyth P, Chaudhry A, et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant. 2003;31:679–85.

    Article  PubMed  CAS  Google Scholar 

  55. Khan R, Shi W, Thaler H, DeAngelis L, Abrey L. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol. 2002;58:175–8.

    Article  PubMed  Google Scholar 

  56. Pels H, Juergens A, Glasmacher A, et al. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol. 2009;91:299–305.

    Article  PubMed  CAS  Google Scholar 

  57. Jahnke K, Thiel E, Martus P, et al. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol. 2006;80(2):159–65.

    Article  PubMed  Google Scholar 

  58. Plotkin S, Betensky R, Hochberg F, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004;10:5643–6.

    Article  PubMed  CAS  Google Scholar 

  59. Fischer L, Thiel E, Klasen H, et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol. 2006;17(7):1141–5.

    Article  PubMed  CAS  Google Scholar 

  60. Arellano-Rodrigo E, Lopez-Guillermo A, Bessell EM, Nomdedeu B, Montserrat E, Graus F. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol. 2003;70:219–24.

    Article  PubMed  CAS  Google Scholar 

  61. Herrlinger U, Brugger W, Bamberg M. PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology. 2000;54:1707–8.

    Article  PubMed  CAS  Google Scholar 

  62. Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011;76:929–30.

    Article  PubMed  CAS  Google Scholar 

  63. Wong ET, Tishler R, Barron L, Wu JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer. 2004;101:139–45.

    Article  PubMed  CAS  Google Scholar 

  64. Enting R, Demopoulos A, DeAngelis L, Abrey L. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology. 2004;63:901–3.

    Article  PubMed  CAS  Google Scholar 

  65. Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology. 2007;11:1178–82.

    Article  Google Scholar 

  66. Nguyen P, Chakravarti A, Finkelstein D, Hochberg F, Batchelor T, Loeffler J. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol. 2005;23:1507–13.

    Article  PubMed  Google Scholar 

  67. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement ­following diagnosis of non-Hodgkin’s lymphoma: a risk model. Ann Oncol. 2002;13:1099–107.

    Article  PubMed  CAS  Google Scholar 

  68. van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91:1178–84.

    PubMed  Google Scholar 

  69. Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18:149–57.

    Article  PubMed  CAS  Google Scholar 

  70. Ferreri AJ, Assanelli A, Crocchiolo R, Ciceri F. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options. Hematol Oncol. 2009;27:61–70.

    Article  PubMed  CAS  Google Scholar 

  71. Bollen EL, Brouwer RE, Hamers S, et al. Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch Neurol. 1997;54:854–9.

    Article  PubMed  CAS  Google Scholar 

  72. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113:3896–902.

    Article  PubMed  CAS  Google Scholar 

  73. Vitolo U, Chiappella A, Ferreri AJ, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29:2766–72.

    Article  PubMed  CAS  Google Scholar 

  74. Abramson JS, Hellmann M, Barnes JA, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116:4283–90.

    Article  PubMed  Google Scholar 

  75. Doolittle ND, Abrey LE, Shenkier TN, et al. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood. 2008;111:1085–93.

    Article  PubMed  CAS  Google Scholar 

  76. Patil S, Spencer A, Schwarer A, et al. Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Leuk Lymphoma. 2009;50:1964–8.

    Article  PubMed  Google Scholar 

  77. Gleissner B, Chamberlain M. Treatment of CNS dissemination in systemic lymphoma. J Neurooncol. 2007;84:107–17.

    Article  PubMed  CAS  Google Scholar 

  78. Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17:3110–6.

    PubMed  CAS  Google Scholar 

  79. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293:161–6.

    Article  PubMed  CAS  Google Scholar 

  80. Correa DD, Rocco-Donovan M, DeAngelis LM, et al. Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol. 2009;91:315–21.

    Article  PubMed  CAS  Google Scholar 

  81. Lai RA, Lauren E, Rosenblum MK, DeAngelis LM. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology. 2004;62:451–6.

    Article  PubMed  Google Scholar 

  82. Correa D, Maron L, Harder H, et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol. 2007;18:1145–51.

    Article  PubMed  CAS  Google Scholar 

  83. Omuro A, Ben-Porat L, Panageas K, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol. 2005;62:1595–600.

    Article  PubMed  Google Scholar 

  84. Correa D, Anderson N, Glass A, Mason W, DeAngelis L, Abrey L. Cognitive functions in primary central nervous system lymphoma patients treated with chemotherapy and stem cell transplantation: preliminary findings. Clin Adv Hematol Oncol. 2003;1:490.

    PubMed  Google Scholar 

  85. Fliessbach K, Helmstaedter C, Urbach H, et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology. 2005;64(7):1184–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, 55 Fruit St., YAWE 9E, 02114, Boston, MA, USA

    Tracy T. Batchelor MD

  2. Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

    Elizabeth R. Gerstner MD

  3. Department of Haematology/Oncology, University Hospital Medical Center, Hugstetter Strasse 55, 79106, Freiburg, Germany

    Gerald Illerhaus MD

Authors
  1. Tracy T. Batchelor MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth R. Gerstner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gerald Illerhaus MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tracy T. Batchelor MD .

Editor information

Editors and Affiliations

  1. Holcombe Blvd. 1515, Houston, 77030, Texas, USA

    Anas Younes

  2. Service d'Hematologie, CHU Lyon-Sud, chemin du Grand Revoyet, Pierre Bénite, 69310, France

    Bertrand Coiffier

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Batchelor, T.T., Gerstner, E.R., Illerhaus, G. (2013). Central Nervous System Lymphoma. In: Younes, A., Coiffier, B. (eds) Lymphoma. Current Clinical Oncology, vol 43. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-408-1_20

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-408-1_20

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-407-4

  • Online ISBN: 978-1-62703-408-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation